Allergan board unanimously rejects cash-stock takeover offer from Valeant Pharma

IRVINE, Calif. – Botox maker Allergan is rejecting a takeover bid from Valeant Pharmaceuticals, saying that the unsolicited $46 billion offer undervalues the company and carries significant risk.

Shortly after Canada’s Valeant and activist investor Bill Ackman made their offer public last month, Valeant announced a so-called poison pill plan, a defensive tactic that makes a buyout prohibitively expensive.

Valeant and Ackman offered to exchange each Allergan share for $48.30 in cash and a portion of shares of Valeant Pharmaceuticals International Inc.

Allergan stockholders would own 43 per cent of the combined company under that proposal. Allergan Inc. says Valeant’s uncertain long-term growth prospects and business model create a risk for Allergan shareholders.

Allergan Inc., based in Irvine, has long been considered one of the star performers in the specialty pharmaceutical sector.

News from © The Associated Press, . All rights reserved.
This material may not be published, broadcast, rewritten or redistributed.

The Associated Press

The Associated Press is an independent global news organization dedicated to factual reporting. Founded in 1846, AP today remains the most trusted source of fast, accurate, unbiased news in all formats and the essential provider of the technology and services vital to the news business. More than half the world’s population sees AP journalism every day.